The trouble for the healthcare revenue cycle management company began when it filed a notification of late filing for its 2025 fiscal year. TruBridge management admitted to identifying significant errors in previously issued financial statements covering 2023 and 2024, as well as multiple quarters in 2025. These discrepancies involve complex accounting areas, specifically revenue recognition, contract costs, stock-based compensation, and capitalized software development expenses.
Investors Eye Class Action Against TruBridge After Financial Restatements
A 10.5% drop in TruBridge, Inc. stock on March 17, 2026, has triggered a formal investigation by the Rosen Law Firm. The legal action centers on allegations that the company provided misleading business information to shareholders, following the firm's sudden inability to file its annual financial report.
Following the revelation that these financial records required major revisions, the company's shares fell $1.84 to close at $15.75. The Rosen Law Firm is now seeking to represent investors who suffered losses during this period, operating on a contingency fee basis. Shareholders looking to join the prospective class action are directed to contact Phillip Kim at the firm's New York offices to discuss potential recovery options.
Comments (0)
No comments yet. Be the first!